DIRS.INFO The most relevant business & tech news

☆ Are Vaccines Fueling New Covid Variants?
▼ + stars: | 2023-01-01 | by ( Allysia Finley | ) www.wsj.com time to read: 1 min

Public-health experts are sounding the alarm about a new Omicron variant dubbed XBB that is rapidly spreading across the Northeast U.S. Some studies suggest it is as different from the original Covid strain from Wuhan as the 2003 SARS virus. Should Americans be worried? It isn’t clear that XBB is any more lethal than other variants, but its mutations enable it to evade antibodies from prior infection and vaccines as well as existing monoclonal antibody treatments. Growing evidence also suggests that repeated vaccinations may make people more susceptible to XBB and could be fueling the virus’s rapid evolution.

The subvariant of omicron, named XBB.1.5, has raised concerns about another potential wave of Covid cases following the busy holiday travel season. The CDC projected Friday that about 40% of confirmed U.S. Covid cases are caused by the XBB.1.5 strain, up from 20% a week ago. There’s no indication it causes more severe illness than any other omicron virus, Dr. Barbara Mahon, director of CDC’s Coronavirus and Other Respiratory Viruses Division, told NBC News. The XBB.1.5 is a relative of the omicron XBB variant, which is a recombinant of the omicron BA.2.10.1 and BA.2.75 subvariants. Yet, only 37.5% of that age group has received the most recent omicron booster, according to the most recent CDC data.

☆ Highly immune evasive omicron XBB.1.5 variant is quickly becoming dominant in U.S. as it doubles weekly
▼ + stars: | 2022-12-30 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Covid omicron XBB.1.5 variant is rapidly becoming dominant in the U.S. because it is highly immune evasive and appears more effective at binding to cells than related subvariants, scientists say. It has since evolved into a family of subvariants including XBB.1 and XBB.1.5. The XBB subvariants are also resistant to Evusheld, an antibody cocktail that many people with weak immune systems rely on for protection against Covid infection because they don't mount a strong response to the vaccines. The scientists described the resistance of the XBB subvariants to antibodies from vaccination and infection as "alarming." The XBB subvariants were even more effective at dodging protection from the omicron boosters than the BQ subvariants, which are also highly immune evasive, the scientists found.

Although many public health experts are expressing concern about the rising COVID cases in China, infectious disease experts have been increasingly worried about the XBB.1.5 variant. Recombinants of the BA.2 variant, XBB and XBB.1.5, together accounted for 44.1% of the total cases in the country for the week ended Dec. 31. For the week ended Dec.24, XBB.1.5 had made up 21.7% of the total cases. The XBB variant has been driving up cases in parts of Asia, including Singapore. It accounted for 3.6% of the total cases in the U.S. this week compared with 4.2% in the previous week.

☆ COVID variant XBB accounts for more than 18% of U.S. cases - CDC
▼ + stars: | 2022-12-23 | by ( ) www.reuters.com time to read: 1 min

Dec 23 (Reuters) - The Omicron subvariant XBB is expected to account for 18.3% of the COVID-19 cases in the United States, up from 11.2% in the previous week, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday. The XBB variant has been driving up cases in parts of Asia, including Singapore, and some experts have said it is more transmissible but less severe. The variant is expected to become the dominant one in parts of the U.S. Northeast in the week ended Dec. 24, according to the CDC. Overall, the BQ.1.1 and BQ.1 remain the dominant circulating variants in the week ended Dec. 24, accounting for 63.1% of the cases, compared with 64.6% a week ago, the CDC said. Reporting by Khushi Mandowara in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

☆ Omicron BQ, XBB subvariants are a serious threat to boosters and knock out antibody treatments, study finds
▼ + stars: | 2022-12-14 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

The omicron subvariants that have become dominant in recent months present a serious threat to the effectiveness of the new boosters, render antibody treatments ineffective and could cause a surge of breakthrough infections, according to a new study. The BQ.1, BQ.1.1, XBB and XBB.1 omicron subvariants are the most immune evasive variants of Covid-19 to date, according to scientists affiliated with Columbia University and the University of Michigan. The immune response of people who were vaccinated and had breakthrough infections with prior omicron variants was also weaker against the subvariants. For people who received the omicron boosters, antibodies that block infection were 24 times lower against BQ.1, 41 times lower against BQ.1.1, 66 times lower against XBB and 85 times lower against XBB.1 compared to their performance against the ancestral strain that emerged in Wuhan, China in 2019. BQ.1.1 and BQ.1 represent 37% and 31% of new infections respectively, while XBB is causing 4.7% of new infections, according to CDC data.

☆ Omicron subvariants that more easily dodge immunity are causing more than 70% of U.S. infections
▼ + stars: | 2022-12-09 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

The most immune evasive omicron subvariants yet are now causing more than 70% of new infections in the U.S., as millions of Americans prepare to travel and gather with family for the holidays later this month. Scientists, in several independent studies, have described the BQ and XBB subvariants as more adept at evading immunity from vaccination and infection than prior versions of the virus. They pose a significant threat to people with compromised immune systems because key antibody treatments are resistant to them. The Food and Drug Administration last week pulled bebtelovimab, a monoclonal antibody used to prevent people who catch Covid from developing severe illness. Many people with weak immune systems, such as organ transplant patients, cannot take Paxlovid with their other medications.

☆ Omicron BQ Covid variants that threaten people with compromised immune systems are now dominant in U.S.
▼ + stars: | 2022-11-25 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

A person receives a coronavirus disease (COVID-19) test as the Omicron coronavirus variant continues to spread in Manhattan, New York City, U.S., December 22, 2021. The omicron BQ coronavirus subvariants have risen to dominance in the U.S. as people gather and travel for the Thanksgiving holiday, putting people with compromised immune systems at increased risk. The omicron BA.5 subvariant, once dominant, now makes up only a fifth of new Covid cases. The BQ subvariants are more immune evasive and likely resistant to key antibody medications, such as Evusheld and bebtelovimab, used by people with compromised immune systems, according to the National Institutes of Health. President Joe Biden, in an October speech, told people with compromised immune systems that they should consult with their physicians and take extra precautions this winter.

☆ New subvariants, family gatherings may bring more Covid-19 after holiday, but experts don’t expect severe surge
▼ + stars: | 2022-11-24 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

Experts expect that Thanksgiving gatherings will stir up social networks and give new coronavirus subvariants fresh pockets of vulnerable people to infect. And we are concerned that after holiday gathering, lots of people coming together, that we may see increases in Covid-19 cases as well,” Dr. Rochelle Walensky, director of the US Centers for Disease Control and Prevention, said Tuesday on CNN. For the week ending Nov. 19, the CDC estimates that BQ.1 and BQ.1.1 were causing about half of all new Covid-19 cases in the US. Covid-19 cases, hospitalizations and deaths have remained flat for the past four weeks. “It’s probably got a bit more of a fitness advantage, so what we’re seeing is gradual replacement without a massive change in the total number of Covid-19 cases,” he said.

☆ Pfizer says omicron booster is better against new subvariants like BQ.1.1 than old shots
▼ + stars: | 2022-11-18 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

Pfizer said its omicron booster triggers a stronger immune response against a number of emerging Covid subvariants circulating the U.S. Pfizer developed its booster against omicron BA.5 at the request of the Food and Drug Administration. Among the emerging subvariants, the omicron booster elicited the strongest immune response against BA.4.6 with antibodies 11 times higher, and the weakest response against XBB.1 with antibodies about 5 times higher. Moderna on Monday said its omicron booster induces an immune response against BQ.1.1 though the company didn't provide specifics. Pfizer and Moderna's new boosters target both omicron BA.5 and the original strain of Covid that emerged in Wuhan, China in 2019.

☆ Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1
▼ + stars: | 2022-11-18 | by ( ) www.reuters.com time to read: +2 min

Nov 18 (Reuters) - Pfizer Inc (PFE.N) and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine. Antibody levels against the variant rose nearly nine-fold in older adults, aged 55 and above, who received the Omicron shot compared to a roughly 2-fold increase in participants with the original shot, according to data posted on online archive bioRxiv. The variant and related BQ.1 are gaining ground in the United States, and are expected to cause a rise in cases in the winter in Europe. The companies had recently released data that showed their Omicron-tailored shot produced a strong antibody response in older adults than the original shot after one month against the BA.4/5 subvariants. Pfizer and BioNTech said the bivalent shot also produced an immune response against newer Omicron subvariants including BA.4.6, BA.2.75.2 and XBB.1.

Two new omicron subvariants have overtaken BA.5 as the prevailing versions of the coronavirus in the U.S.BA.5 became dominant in July, then consistently accounted for the majority of new Covid infections until last week. The two together make up around 44% of new Covid infections, whereas BA.5 makes up just 30%. BQ.1.1 and BQ.1 cases are also rising in the U.K. and elsewhere in Europe. Both of the subvariants are considered part of the BA.5 family — they're sublineages that evolved from BA.5. "There’s nothing in the signature of the clinical cases that are being reported that suggests that anything is changing in terms of symptoms with these omicron subvariants," Pekosz said.

☆ Australia seeks to reassure citizens on COVID after cruise ship outbreak
▼ + stars: | 2022-11-12 | by ( ) www.reuters.com time to read: +2 min

SYDNEY, Nov 12 (Reuters) - Australia's Home Affairs Minister on Saturday sought to reassure the public that COVID-19 protocols were adequate after a cruise ship with hundreds of infected passengers docked in Sydney. The incident has sparked comparisons with a notorious 2020 outbreak onboard the Ruby Princess cruise ship. That outbreak, also in New South Wales, led to 914 infections and 28 deaths, an inquiry found. Carnival Australia, part of global leisure company Carnival Corporation & plc, said COVID-positive passengers were isolating onboard and being cared for by medical staff, according to New South Wales Health. The agency said it was working with cruise ship staff to monitor the health of passengers and crew members.

☆ Fact Check-No evidence COVID-19 Omicron XBB variant has higher mortality rate, or is five times more ‘toxic,’ than Delta
▼ + stars: | 2022-11-11 | by ( Reuters Fact Check | ) www.reuters.com time to read: +2 min

Social media users in Singapore are copy-pasting a text post which warns that the COVID-19 Omicron XBB variant, first discovered in August, is five times more “toxic” and has a higher mortality rate than the Delta variant. However, there is no evidence to support this, according to Singapore’s Ministry of Health. Likewise, the World Health Organisation (WHO) says current data does not suggest XBB is more deadly than Omicron, which itself is less lethal than Delta. There is, however, early evidence pointing at a higher reinfection risk, as compared to other circulating Omicron sublineages.”VERDICTFalse. There is no evidence the SARS-CoV-2 Omicron XBB variant is more deadly or causes more severe COVID-19 than the Delta variant.

☆ ‘Scrabble variants’ now cause the majority of new Covid-19 infections in the US
▼ + stars: | 2022-10-28 | by ( Brenda Goodman | ) edition.cnn.com time to read: +3 min

CNN —The Omicron BA.5 subvariant is no longer the dominant cause of Covid-19 infections in the United States, according to estimates released Friday by the US Centers for Disease Control and Prevention. The gaggle of new variants have been gaining ground against BA.5, which has dominated Covid-19 infections in the United States since July. Together, they now account for more than 1 in 4 new Covid-19 infections nationwide, according to CDC data. BQ.1.1 is now causing about 1 in 5 new Covid-19 infections in the Northeast, where cases and hospitalizations are rising. But that strain is causing just 3% of new Covid-19 infections in the Pacific Northwest.

☆ New Covid boosters aren’t better than old shots at neutralizing omicron BA.5, early studies find
▼ + stars: | 2022-10-27 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

The new COVID-19 booster which includes protection for Omicron at AltaMed Health Services in South Gate on Thursday, October 6, 2022. Two studies are raising doubts about whether the new omicron BA.5 booster really will offer better protection against Covid than the first generation shot. Scientists at Columbia University in New York City found the new boosters did not produce a better antibody response in humans against BA.5 than the first-generation vaccines. Hotez said there should also be investigations into how the boosters perform against emerging omicron subvariants such as XBB and BQ.1., as the currently dominant BA.5 declines in circulation. It could be the case that the new boosters perform better against these emerging variants than the first generation shots do, Hotez said.

☆ Global COVID cases will increase in coming months, but at a slower pace, analysis says
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - Daily global COVID-19 infections are projected to rise slowly to about 18.7 million by February from the current 16.7 million aveage daily cases, driven by the northern hemisphere's winter months, the University of Washington said in an analysis. The increase in cases is not expected to cause a surge in deaths, the University of Washington's Institute for Health Metrics and Evaluation (IHME) said. It forecast that global daily deaths would average 2,748 people on Feb. 1, compared with around 1,660 currently. IHME estimates that daily infections in the United States will increase by a third to more than a million, driven by students back in schools and cold weather-related indoor gatherings. A rapid increase in hospital admissions in Germany – the highest since the COVID outbreak in 2020 - remains an area of concern, it said.

☆ Global COVID cases will increase in coming months, but at a slower pace -report
▼ + stars: | 2022-10-25 | by ( ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - Daily global COVID-19 infections are projected to rise slowly to about 18.7 million by February from the current 16.7 million aveage daily cases, driven by the northern hemisphere's winter months, the University of Washington said in an analysis. The increase in cases is not expected to cause a surge in deaths, the University of Washington's Institute for Health Metrics and Evaluation (IHME) said. It forecast that global daily deaths would average 2,748 people on Feb. 1, compared with around 1,660 currently. A surge in Germany has peaked already, it said in its report on Oct. 24. A rapid increase in hospital admissions in Germany – the highest since the COVID outbreak in 2020 - remains an area of concern, it said.

☆ How concerned should you be about Covid-19 ‘Scrabble' variants? Here's what we know so far
▼ + stars: | 2022-10-25 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

Though BA.5 still accounts for most U.S. Covid-19 cases, percentages are rising for the other omicron variants circulating throughout the country, per the CDC. "The ones that are particularly concerning are BQ.1 and another related one called BQ.1.1. Internationally, another concerning variant, XBB, which first emerged in Singapore and hasn't been detected in the U.S., is being closely watched worldwide as it spreads quickly in other countries. The new variants were coined the "Scrabble" variants by Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital, during an interview with the Houston Chronicle. The nickname refers to the letters that are used to define the variants like B, X and Q, which would rack up many points in a game of Scrabble.

☆ Omicron subvariants pose a new threat to people with immune deficiencies
▼ + stars: | 2022-10-23 | by ( Benjamin Ryan | ) www.nbcnews.com time to read: +7 min

Troubling recent reports reveal the emergence of new omicron subvariants that not only evade AstraZeneca’s Evusheld, the antibody drug authorized to prevent Covid infection, but also the sole antibody drug that has retained effectiveness as treatment for Covid, Eli Lilly’s bebtelovimab. Doctors have cautioned that should Laura get Covid, this could aggravate her autoimmune disease and lead to catastrophic kidney damage. Evusheld is a long-acting antibody injection given every six months that studies have suggested provides a robust buffer to the immunosuppressed. For now, immunocompromised people are anxiously watching the pandemic forecast to see if the subvariants that research indicates evade monoclonal antibodies will become predominant. “If fewer people are prescribed Evusheld,” she said, “there’s less incentive for drug companies to start developing newer therapeutics.

☆ A new, stealthy COVID variant is spreading fast, spooking scientists and Wall Street analysts, but experts say there is cause for optimism
▼ + stars: | 2022-10-21 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +5 min

Experts say: prepare for more COVID infections this winter. But "among the new variants, XBB has the most significant immune evasion properties," market forecasters at Morgan Stanley said Thursday in a memo. Experts say we should expect many more infections this fall and winter, including infections in vaccinated, boosted Americans. But there are some simple things you can do to prepare to battle XBB and other evasive COVID variants on the horizon. Both have a slight growth advantage over BA.5, which is the dominant version of COVID right now in the US.

☆ COVID variants BQ.1, BQ 1.1 make up 16.6% of U.S. cases - CDC
▼ + stars: | 2022-10-21 | by ( ) www.reuters.com time to read: +2 min

The variants have spread quickly in the country in the last few weeks, particularly in New York. The CDC said on Friday that BQ.1 last week was estimated to make up 5.8% of circulating variants, while BQ.1.1 had made up 3.6% of all variants. New variants are monitored closely by regulators and vaccine manufacturers in case they start to evade protection offered by current shots. The World Health Organization this week said BQ.1.1 is circulating in at least 29 countries. The BA.5 variant is estimated to made up 62.2% of cases for the week of Oct 22, down from 70.2% in the week of Oct 15.

☆ Quick and stealthy new Covid-19 variants are poised to drive a winter surge
▼ + stars: | 2022-10-20 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

CNN —A flurry of new Covid-19 variants appears to be gaining traction globally, raising fears of a winter surge. As the US moves into the fall, Covid-19 cases are dropping. But virus experts fear that the downward trend may soon reverse itself, thanks to this gaggle of new variants. Lumped together, the variants accounted for almost 1 in 3 new Covid-19 infections nationwide last week, according to the latest estimates from the US Centers for Disease Control and Prevention. The updated bivalent booster vaccines and antiviral drugs like Paxlovid are expected to continue to be protective against severe outcomes from Covid-19 infections caused by the new variants.

Other omicron subvariants that have piqued the interest — and concerns — of scientists read like a viral alphabet soup: BQ.1, BQ.1.1, BF.7. Ever since the omicron variant emerged, it's been omicron all the way down, with omicron subvariants splitting off into their own subvariants. Barouch's study was small, including just 35 people who'd had either the Covid vaccine or an omicron infection. Most, regardless of prior infection, had at least three doses of Covid vaccine. The World Health Organization is tracking more than 300 omicron subvariants worldwide, Maria Van Kerkhove, head of the WHO’s emerging diseases and zoonosis unit, said during a media briefing Wednesday.

Search resuls for: "XBB"

24 mentions found